Skip Navigation

This Article
Right arrow Full Text Freely available
Right arrow FREE Full Text (PDF ) Freely available
Right arrow Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in ISI Web of Science
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrow Search for citing articles in:
ISI Web of Science (29)
Right arrowRequest Permissions
Google Scholar
Right arrow Articles by Jablonowska, B.
Right arrow Articles by Lindton, B.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Jablonowska, B.
Right arrow Articles by Lindton, B.
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

Human Reproduction, Vol. 14, No. 3, 838-841, March 1999
© 1999 European Society of Human Reproduction and Embryology

Prevention of recurrent spontaneous abortion by intravenous immunoglobulin: a double-blind placebo-controlled study

B. Jablonowska1,4, A. Selbing1, M. Palfi2, J. Ernerudh2, S. Kjellberg1 and B. Lindton3

1 Department of Obstetrics and Gynecology, 2 Department of Transfusion Medicine and Clinical Immunology, University Hospital, S-581 85 Linköping and 3 Department of Obstetrics and Gynecology, Huddinge University Hospital, S-141 86 Huddinge, Sweden

The aim of this study was to evaluate the therapeutic efficacy of intravenous immunoglobulin (IVIG) in the prevention of recurrent spontaneous abortion (RSA). In a double-blind, randomized, placebo-controlled study, 41 women with a history of unexplained recurrent spontaneous abortion were treated with IVIG or saline infusions during pregnancy. The birth of a child was considered a successful outcome. The overall success rate was 77% in the IVIG group compared with 79% in the placebo group. For women with primary RSA the success rates were 82 (IVIG) and 89% (placebo), and for women with secondary RSA the rates were 73 (IVIG) and 70% (placebo). We found no statistically significant difference in treatment results between IVIG and placebo.

Key words: intravenous immunoglobulin/recurrent spontaneous abortion

4 To whom correspondence should be addressed


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?


This article has been cited by other articles:


Home page
 Mol Hum ReprodHome page
M. Takeda, H. Yamada, K. Iwabuchi, S. Shimada, M. Naito, N. Sakuragi, H. Minakami, and K. Onoe
Administration of high-dose intact immunoglobulin has an anti-resorption effect in a mouse model of reproductive failure
Mol. Hum. Reprod., November 1, 2007; 13(11): 807 - 814.
[Abstract] [Full Text] [PDF]


Disclaimer: Please note that abstracts for content published before 1996 were created through digital scanning and may therefore not exactly replicate the text of the original print issues. All efforts have been made to ensure accuracy, but the Publisher will not be held responsible for any remaining inaccuracies. If you require any further clarification, please contact our Customer Services Department.